drugset / Trial / NCT07024147
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Phase 1
Not yet recruiting
20 enrolled
Peking University Cancer Hospital & Institute
Shanghai JW Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
JWCAR239 is a CD19/CD20 CAR-T product. This trial is intended to evaluate the safety, PK/PD and efficacy of JWCAR239 in patients with B Cell Non-Hodgkin Lymphoma (B-NHL)
Timeline
- Start
- 2025-07-01
- Primary completion
- 2027-07-01
- Completion
- 2030-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JWCAR239 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |